GKL-006Allo Injection in Patients With Advanced Solid Tumors
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006Allo Injection in Patients With Solid Tumors
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
This Phase 1 study will evaluate GKL-006Allo Injection in participants with advanced or metastatic solid tumors who have failed or are intolerant to standard therapy.
The study includes single-dose and multiple-dose treatment, with a potential dose-expansion stage to further evaluate selected dose level according to protocol-specified criteria. The single-dose and multiple-dose stages are designed to characterize safety, tolerability, and biological activity across protocol-specified dose levels.
Participants will receive GKL-006Allo Injection according to the study protocol and will undergo scheduled safety monitoring, tumor assessments, pharmacokinetic and pharmacodynamic sampling, and immunogenicity testing during treatment and follow-up.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Cancer Hospital Chinese Academy of Medical Sciences
- Puhelinnumero: +86-316-5916013
- Sähköposti: lining@cisams.ac.cn
Opiskelupaikat
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
Ottaa yhteyttä:
- GCP Center
- Puhelinnumero: 0316-5916013
- Sähköposti: lining@cisams.ac.cn
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Able to understand and voluntarily sign the informed consent form.
- Aged 18 to 75 years.
- Histologically, cytologically or clinical confirmed unresectable locally advanced or metastatic solid tumor that has failed standard therapy.
- At least one measurable tumor lesion during screening according to RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and life expectancy of at least 3 months.
- Adequate hematologic and organ function.
- Participants of childbearing potential must agree to use at least one medically accepted contraceptive method during study treatment and for 6 months after the end of study treatment.
- Able to communicate with the investigator, comply with study visits, and understand and follow study requirements.
Exclusion Criteria:
- Recently received radical radiotherapy or other anti-tumor therapy.
- Known hypersensitivity to any component of the study treatment.
- Prior history or concurrent malignancy that has not been cured.
- Active infection, known or suspected autoimmune disease.
- Last anti-tumor treatment toxicity not yet recovered to suitable status.
- Other organ dysfunction or situations deemed inappropriate by the investigator.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: GKL-006Allo Injection
Natural killer T cells (NKT) are a type of special lymphocyte discovered in recent years that mediate both innate and adaptive immunity, and are considered the fourth type of lymphocyte.
GKL-006Allo is an allogeneic iNKT cell.
|
GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy.
It will be administered according to the dose level, dosing schedule, and treatment stage specified in the protocol.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Participants With Dose-Limiting Toxicities (DLTs)
Aikaikkuna: From the first dose through the end of the DLT observation period, assessed up to 28 days.
|
Dose-limiting toxicities will be assessed according to protocol-defined DLT criteria.
|
From the first dose through the end of the DLT observation period, assessed up to 28 days.
|
|
Incidence and Severity of Adverse Events
Aikaikkuna: From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.
|
Safety will be assessed by the incidence and severity of adverse events, serious adverse events, laboratory abnormalities, electrocardiogram abnormalities, physical examination findings, and vital sign abnormalities.
|
From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Progression-Free Survival (PFS)
Aikaikkuna: From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
|
Progression-free survival is defined as the time from the first dose of study treatment to the first documented disease progression or death from any cause, whichever occurs first, according to RECIST v1.1.
|
From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
|
|
Overall Survival (OS)
Aikaikkuna: From the first dose of study treatment until death from any cause, assessed up to 18 months.
|
Overall survival is defined as the time from the first dose of study treatment to death from any cause.
|
From the first dose of study treatment until death from any cause, assessed up to 18 months.
|
|
Change From Baseline in EORTC QLQ-C30 Scale Scores
Aikaikkuna: Baseline and scheduled post-baseline assessments, up to 18 months.
|
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
Scores for each scale range from 0 to 100.
Higher scores on the functional scales and global health status/quality-of-life scale indicate better functioning or quality of life.
|
Baseline and scheduled post-baseline assessments, up to 18 months.
|
|
Immunogenicity
Aikaikkuna: From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
|
GKL-006 Alloantibodies (ADA) and their titers, anti-GKL-006 Allo neutralizing antibodies (Nab) and their titers, anti-HLA antibodies, etc. will be tested.
|
From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
|
|
Disease Control Rate (DCR)
Aikaikkuna: From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
|
Disease control rate is defined as the proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST v1.1.
|
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
|
|
Objective Response Rate (ORR)
Aikaikkuna: From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
|
Objective response rate is defined as the proportion of participants with a best overall response of complete response or partial response according to RECIST v1.1.
|
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
|
|
Pharmacokinetic characterization of maximum observed plasma concentration (Cmax)
Aikaikkuna: From 60 minutes before the first dose through 150 days.
|
Maximum observed plasma concentration of GKL-006 following intravenous administration according to protocol.
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax)
Aikaikkuna: From 60 minutes before the first dose through 150 days.
|
Time to reach the maximum observed plasma concentration of GKL-006 following intravenous administration.
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC)
Aikaikkuna: From 60 minutes before the first dose through 150 days.
|
Area under the plasma concentration-time curve of GKL-006 following intravenous administration.
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacokinetic characterization of terminal elimination half-life (t½)
Aikaikkuna: From 60 minutes before the first dose through 150 days.
|
Terminal elimination half-life of GKL-006 calculated from plasma concentration-time data following intravenous administration.
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacodynamic Biomarkers of NK cells
Aikaikkuna: From 60 minutes before the first dose through 150 days.
|
Immune cell subsets
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacodynamic Biomarkers of Peripheral blood TNF-α
Aikaikkuna: From 60 minutes before the first dose through 150 days.
|
Immune-related cytokines
|
From 60 minutes before the first dose through 150 days.
|
|
Pharmacodynamic Biomarkers of Peripheral blood IFN-γ
Aikaikkuna: From 60 minutes before the first dose through 150 days.
|
Immune-related cytokines
|
From 60 minutes before the first dose through 150 days.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Päätutkija: Ning Li, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- GKL006ALLOST01
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .